Histologically proven or suspected gastrointestinal tumor (e.g. esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, hepatocellular carcinoma, gastrointestinal neuroendocrine neoplasia)
Conditions
Interventions
Group 1: Patients with histologically proven or suspected gastrointestinal tumors scheduled for elective tumor resection/biopsy will be recruited for this trial.
Sponsors
Universitätsklinik für Allgemeine-, Viszerale- und Transplantationschirurgie Tübingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Histologically proven or suspected gastrointestinal tumor (e.g. esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, hepatocellular carcinoma, gastrointestinal neuroendocrine neoplasia) on cross-sectional imaging with planned surgical resection/biopsy - = 18 years of age - Capacity for consent and written informed consent - Patient considered to tolerate surgery
Exclusion criteria
Exclusion criteria: - American Society of Anesthesiologists (ASA) score > III - Inability to comply with study and/or follow-up procedures - (language) problems in understanding the patient information document explaining the present clinical trial - Any condition which could result in an undue risk for the patient in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comprehensive characterization of tumor heterogeneity in gastrointestinal tumors | — |
Secondary
| Measure | Time frame |
|---|---|
| - Determination of the spatial distribution, density, composition, mutation and activation status of intratumoral cell types (immune, stroma, epithelial cells) and tumor-infiltrating microbes on single cell level. - Assessment/prediction of therapy response using ex vivo tumor models (e. g. organoids, tissue slice cultures) - Assessment of perioperative tumor cell dissemination (circulating tumor cells, CTCs) and heterogeneity (e.g. clonal, transcriptional) of disseminated tumor cells - Assessment of parameters of gastrointestinal tumors to delineate their biological relevance, i.e. survival, recurrence, metastatic potential, or response to adjuvant therapy - Identification of therapeutic targets and clinically relevant markers, which might improve patient stratification, to predict prognosis, or therapy response | — |
Countries
Germany
Contacts
Public ContactSusanne Roth
Universitätsklinik für Allgemeine-, Viszerale- und Transplantationschirurgie Tübingen
Outcome results
None listed